Skip to main content
TipRanks
Go Ultimate75% OFF

Celltrion Pharm Inc. (068760) Stock Price & Analysis

068760 Stock Chart & Stats

â‚©41,100.00â‚©850.00(2.11%)
At close: 3:30 PM GMT+9
â‚©37.5Kâ‚©40Kâ‚©42.5KAug 18Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
KRW 40,850.00 - KRW 42,500.00
52-Week Range
KRW 35,600.00 - KRW 78,300.00
Previous Close
KRW 40,250.00
Volume
N/A
Average Volume (3M)
66.54K
Market Cap
KRW 1.78T
Enterprise Value
KRW 1.85T
Total Cash (Recent Filing)
KRW 116.93B
Total Debt (Recent Filing)
KRW 161.31B
Price to Earnings (P/E)
130.9
Beta
0.22
Next Earnings
Mar 22, 2027 (Est.)
EPS Estimate
N/A
Dividend Yield
0.37%

Bulls Say, Bears Say

Bulls Say

Revenue And Profitability Growth

The strong 2025 revenue step-up, combined with improved EBIT and EBITDA margins, indicates that Celltrion Pharm is expanding its operating earnings base. A broader and more profitable revenue platform can support reinvestment, strengthen execution capacity, and provide more durable earnings potential over the next several quarters.

Improving Balance Sheet

Lower debt-to-equity and steady equity growth improve financial resilience relative to the company’s earlier position. This gives Celltrion Pharm greater flexibility to support its pharmaceutical operations and absorb earnings variation, while reducing the balance-sheet pressure associated with higher leverage.

Recent Cash Generation

Strong operating and free cash flow in the two most recent years shows that recent earnings have translated into meaningful internal cash generation. This supports ongoing investment and financial flexibility, while free cash flow covering a large portion of net income provides evidence of improved earnings quality in the near term.

Bears Say

Cash-Flow Volatility

The uneven cash-flow record makes the durability of earnings conversion less certain than the recent income statement suggests. Negative cash flow in 2022, very low free cash flow in 2023, and a 2025 decline versus 2024 could constrain internally funded investment if this volatility returns.

Margins Below Earlier Peaks

Although profitability improved in 2025, net margin remains below the company’s earlier highs, pointing to persistent mix or expense pressure. This limits the extent to which revenue growth converts into bottom-line expansion and means future earnings growth may require continued operating improvement.

Debt And Moderate Returns

Deleveraging is constructive, but the remaining absolute debt load still warrants monitoring if profitability softens. At the same time, returns are described as moderate rather than standout, suggesting that the expanded asset and equity base has not yet produced consistently strong capital efficiency.

068760 FAQ

What was Celltrion Pharm Inc.’s price range in the past 12 months?
Celltrion Pharm Inc. lowest stock price was â‚©35600.00 and its highest was â‚©78300.00 in the past 12 months.
What is Celltrion Pharm Inc.’s market cap?
Celltrion Pharm Inc.’s market cap is ₩1.78T.
When is Celltrion Pharm Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Celltrion Pharm Inc.’s earnings last quarter?
Celltrion Pharm Inc. released its earnings results on Nov 09, 2026. The company reported â‚©404.521 earnings per share for the quarter.
Is Celltrion Pharm Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Celltrion Pharm Inc. pay dividends?
Celltrion Pharm Inc. pays a dividend of â‚©200 which represents an annual dividend yield of 0.37%. See more information on Celltrion Pharm Inc. dividends here
What is Celltrion Pharm Inc.’s EPS estimate?
Celltrion Pharm Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celltrion Pharm Inc. have?
Celltrion Pharm Inc. has 43,683,804 shares outstanding.
What happened to Celltrion Pharm Inc.’s price movement after its last earnings report?
Celltrion Pharm Inc. reported an EPS of â‚©404.521 in its last earnings report. Following the earnings report the stock price went down -0.505%.
Which hedge fund is a major shareholder of Celltrion Pharm Inc.?
Currently, no hedge funds are holding shares in KR:068760
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology